E-Combretastatin A-4

E-Combretastatin A-4

SCHEMBL9707931

COc1ccc(/C=C/c2cc(OC)c(OC)c(OC)c2)cc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB1 Q9H4B7 17/20 1.00
TUBB4A P04350 7/20 1.00
TUBB P07437 7/20 1.00
TUBA3C P0DPH7 7/20 1.00
TUBA1B P68363 7/20 1.00
TUBA4A P68366 7/20 1.00
TUBB4B P68371 7/20 1.00
TUBB3 Q13509 7/20 1.00
TUBB2A Q13885 7/20 1.00
TUBB8 Q3ZCM7 7/20 1.00
TUBA3E Q6PEY2 7/20 1.00
TUBA1A Q71U36 7/20 1.00
TUBA1C Q9BQE3 7/20 1.00
TUBB6 Q9BUF5 7/20 1.00
TUBB2B Q9BVA1 7/20 1.00
SLC22A2 O15244 1/20 1.00
SLCO2B1 O94956 1/20 1.00
ABCB1 P08183 1/20 1.00
SLC22A6 Q4U2R8 1/20 1.00
SLC22A8 Q8TCC7 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Combretastatin A4 SCHEMBL18946 1.00 TUBB1 (1.00) TUBB1TUBB4ATUBBTUBA3CTUBA1B
Combretastatin A4 SCHEMBL29355902 1.00 TUBB1 (1.00) TUBB1TUBB4ATUBBTUBA3CTUBA1B
Combretastatin A4 SCHEMBL18945 1.00 TUBB1 (1.00) TUBB1TUBB4ATUBBTUBA3CTUBA1B
Combretastatin A4 SCHEMBL29501750 1.00 TUBB1 (1.00) TUBB1TUBB4ATUBBTUBA3CTUBA1B
Combretastatin A4 SCHEMBL4452799 0.98 TUBB1 (0.97) TUBB1TUBB4ATUBBTUBA3CTUBA1B
Combretastatin A4 SCHEMBL6456251 0.95 TUBB1 (0.91) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL13813246 0.95 TUBB1 (0.90) TUBB1TUBB4ATUBBTUBA3CTUBA1B
Combretastatin A4 SCHEMBL5073658 0.94 TUBB1 (0.88) TUBB1TUBB4ATUBBTUBA3CTUBA1B
Combretastatin A4 SCHEMBL8188814 0.92 TUBB1 (0.85) TUBB1TUBB4ATUBBTUBA3CTUBA1B
Combretastatin A4 SCHEMBL6905413 0.91 TUBB1 (0.83) TUBB1TUBB4ATUBBTUBA3CTUBA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240315965-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2024-09-26 US claimed
WO-2022182527-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2022-09-01 WO claimed
CN-106336347-B New method for synthesizing hydroxystilbenes 中国科学院成都有机化学有限公司 2020-08-18 CN claimed
US-12630450-B1 Somatic embryonic cell suspension for wastewater treatment King Faisal University (SA) 2026-05-19 US disclosed
US-20240355451-A1 METHODS FOR IMPROVING GUT MICROBIOTA DIVERSITY NESTLE SA (CH) 2024-10-24 US disclosed
WO-2024176961-A1 PROTEIN RECOGNIZING K-Ras GENE MUTATION CANCER 国立研究開発法人理化学研究所 2024-08-29 WO disclosed
CN-117982683-B Drug delivery system with reduction responsiveness and preparation method and application thereof 中国科学院苏州纳米技术与纳米仿生研究所 2024-08-06 CN disclosed
EP-4391834-A1 METHODS FOR IMPROVING GUT MICROBIOTA DIVERSITY Société des Produits Nestlé S.A. (CH) 2024-07-03 EP disclosed
CN-117982683-A Drug delivery system with reduction responsiveness and preparation method and application thereof 中国科学院苏州纳米技术与纳米仿生研究所 2024-05-07 CN disclosed
US-20230255989-A1 GLYCAN COMPOSITIONS AND USES THEREOF DSM NUTRITIONAL PRODUCTS LLC (US) 2023-08-17 US disclosed
WO-2023025722-A1 METHODS FOR IMPROVING GUT MICROBIOTA DIVERSITY Société des Produits Nestlé S.A. (CH) 2023-03-02 WO disclosed
US-20150359884-A1 MULTI-PHOTON ISOMERISATION OF COMBRETASTATINS AND THEIR USE IN THERAPY BISBY ROGER H (GB) 2015-12-17 US disclosed
WO-2015108595-A1 ANTI-TUMOR THERAPY KHODAREV NIKOLAI (US) 2015-07-23 WO disclosed
US-8853270-B2 Substituted stilbenes and their reactions UNIVERSITY OF SALFORD (GB) 2014-10-07 US disclosed
US-20130023663-A1 SUBSTITUTED STILBENES AND THEIR REACTIONS HADFIELD JOHN ANTHONY (GB) 2013-01-24 US disclosed
US-20070203217-A1 SUBSTITUTED STILBENES AND THEIR REACTIONS UNIVERSITEIT UTRECHT UU HOLDING B.V. (NL) 2007-08-30 US disclosed
US-20070203217-A1 SUBSTITUTED STILBENES AND THEIR REACTIONS UNIVERSITEIT UTRECHT UU HOLDING B.V. (NL) 2007-08-30 US disclosed
US-7220784-B2 Substituted stilbenes and their reactions CANCER RESEARCH VENTURES LIMITED (GB) 2007-05-22 US disclosed
US-7220784-B2 Substituted stilbenes and their reactions CANCER RESEARCH VENTURES LIMITED (GB) 2007-05-22 US disclosed
WO-1992016486-A1 SUBSTITUTED DIPHENYLETHYLENES AND ANALOGUES OR DERIVATIVES THEREOF ASTON MOLECULES LIMITED (GB) 1992-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023663-A1 SUBSTITUTED STILBENES AND THEIR REACTIONS BLVRB, BBOX1, SQLE TUBB1 1121/4885TUBB4A 869/4885TUBB 1023/4885
US-12630450-B1 Somatic embryonic cell suspension for wastewater treatment ALPG, PROX1, KIT TUBB1 2383/4885TUBB4A 2035/4885TUBB 1587/4885
US-20070203217-A1 SUBSTITUTED STILBENES AND THEIR REACTIONS CASP4, ATG4B, CTSB TUBB1 1146/4885TUBB4A 568/4885TUBB 1056/4885
US-20150359884-A1 MULTI-PHOTON ISOMERISATION OF COMBRETASTATINS AND THEIR USE IN THERAPY SLC5A6, FLT4, FOLR2 TUBB1 867/4885TUBB4A 548/4885TUBB 705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.